{
    "id": 26871,
    "fullName": "EZH2 T678_R679delinsKK",
    "impact": "deletion",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EZH2 T678_R679delinsKK results in a deletion of two amino acids in the SET domain of the Ezh2 protein from amino acids 678 to 679, combined with the insertion of two lysines (K) at the same site (UniProt.org). T678_R679delinsKK has been demonstrated to confer Tazemetostat (EPZ-6438) resistance in culture (PMID: 28231254), but has not been biochemically characterized and therefore, its effect on Ezh2 protein function is unknown (PubMed, Oct 2019).",
            "references": [
                {
                    "id": 9725,
                    "pubMedId": 28231254,
                    "title": "Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28231254"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2146,
        "geneSymbol": "EZH2",
        "terms": [
            "EZH2",
            "ENX-1",
            "ENX1",
            "EZH2b",
            "KMT6",
            "KMT6A",
            "WVS",
            "WVS2"
        ]
    },
    "variant": "T678_R679delinsKK",
    "createDate": "08/16/2017",
    "updateDate": "10/05/2019",
    "referenceTranscriptCoordinates": {
        "id": 171496,
        "transcript": "NM_001203247",
        "gDna": "chr7:g.148809368_148809373delinsCTTCTT",
        "cDna": "c.2032_2037delinsAAGAAG",
        "protein": "p.T678_R679delinsKK",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11713,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a murine acute myeloid leukemia cell line expressing EZH2 T678_R679delinsKK were resistant to Tazemetostat (EPZ-6438) in culture (PMID: 28231254).",
            "molecularProfile": {
                "id": 28195,
                "profileName": "EZH2 T678_R679delinsKK"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9725,
                    "pubMedId": 28231254,
                    "title": "Rapid generation of drug-resistance alleles at endogenous loci using CRISPR-Cas9 indel mutagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28231254"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28195,
            "profileName": "EZH2 T678_R679delinsKK",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 171496,
            "transcript": "NM_001203247",
            "gDna": "chr7:g.148809368_148809373delinsCTTCTT",
            "cDna": "c.2032_2037delinsAAGAAG",
            "protein": "p.T678_R679delinsKK",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}